Circulating Biomarkers to Identify Responders in Cardiac Cell therapy

Jesse V. Jokerst; Nicholas Cauwenberghs; Tatiana Kuznetsova; Francois Haddad; Timothy Sweeney; Jiayi Hou; Yael Rosenberg-Hasson; Eric Zhao; Robert Schutt; Roberto Bolli; Jay H. Traverse; Carl J. Pepine; Timothy D. Henry; Ivonne H. Schulman; Lem Moyé; Doris A. Taylor; Phillip C. Yang

doi:10.1038/s41598-017-04801-7

Scientific Reports (Jun 2017)

Circulating Biomarkers to Identify Responders in Cardiac Cell therapy

Jesse V. Jokerst,
Nicholas Cauwenberghs,
Tatiana Kuznetsova,
Francois Haddad,
Timothy Sweeney,
Jiayi Hou,
Yael Rosenberg-Hasson,
Eric Zhao,
Robert Schutt,
Roberto Bolli,
Jay H. Traverse,
Carl J. Pepine,
Timothy D. Henry,
Ivonne H. Schulman,
Lem Moyé,
Doris A. Taylor,
Phillip C. Yang

Affiliations

Jesse V. Jokerst: Department of NanoEngineering, University of California
Nicholas Cauwenberghs: Research Unit of Hypertension and Cardiovascular Epidemiology, Department of Cardiovascular Sciences, University of Leuven
Tatiana Kuznetsova: Research Unit of Hypertension and Cardiovascular Epidemiology, Department of Cardiovascular Sciences, University of Leuven
Francois Haddad: Department of Medicine, Stanford University
Timothy Sweeney: Department of Medicine, Stanford University
Jiayi Hou: Clinical and Translational Research Institute, University of California
Yael Rosenberg-Hasson: Department of Medicine, Stanford University
Eric Zhao: Department of NanoEngineering, University of California
Robert Schutt: Houston Methodist Hospital
Roberto Bolli: School of Medicine, University of Louisville
Jay H. Traverse: Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital
Carl J. Pepine: University of Florida College of Medicine
Timothy D. Henry: Cedars-Sinai Heart Institute
Ivonne H. Schulman: Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine
Lem Moyé: University of Texas School of Public Health, University of Texas Health Science Center
Doris A. Taylor: Texas Heart Institute, CHI St. Luke’s Health Baylor College of Medicine Medical Center
Phillip C. Yang: Department of Medicine, Stanford University

DOI: https://doi.org/10.1038/s41598-017-04801-7
Journal volume & issue: Vol. 7, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Bone marrow mononuclear cell (BM-MNC) therapy in ST-elevation acute myocardial infarction (STEMI) has no biological inclusion criteria. Here, we analyzed 63 biomarkers and cytokines in baseline plasma samples from 77 STEMI patients treated with BM-MNCs in the TIME and Late-TIME trials as well as 61 STEMI patients treated with placebo. Response to cell therapy was defined by changes in left ventricular ejection fraction, systolic/diastolic volumes, and wall motion indexes. We investigated the clinical value of circulating proteins in outcome prediction using significance testing, partial least squares discriminant analysis, and receiver operating characteristic (ROC) analysis. Responders had higher biomarker levels (76–94% elevated) than non-responders. Several biomarkers had values that differed significantly (P 0.70 including interleukin 15. These biomarkers were not involved in the placebo-treated subjects suggesting that they may have predictive power. We conclude that plasma profiling after STEMI may help identify patients with a greater likelihood of response to cell-based treatment. Prospective trials are needed to assess the predictive value of the circulating biomarkers.

Published in Scientific Reports

ISSN: 2045-2322 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Medicine; Science
Website: https://www.nature.com/srep/

About the journal